Insulin secretagogues were associated with increased mortality compared with metformin in type 2 diabetes

被引：1
|
作者：
Prutsky, Gabriela [1 ]
Domecq, Juan Pablo [1 ]
Tsapas, Apostolos [1 ]
机构：
[1] Mayo Clin, Knowledge & Evaluat Res Unit, Rochester, MN 55905 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2012年 / 156卷 / 02期
关键词：
D O I：
10.7326/0003-4819-156-2-201201170-02007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Monotherapy with sulphonylurea is associated with increased mortality as compared with metformin in type 2 diabetes
    Mintici, L.
    Ioacara, S.
    Guja, C.
    Stegaru, D.
    Reghina, A.
    Georgescu, O.
    Martin, S.
    Purcaru, M.
    Fica, S.
    DIABETOLOGIA, 2016, 59 : S355 - S355
  • [2] Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
    Schramm, Tina Ken
    Gislason, Gunnar Hilmar
    Vaag, Allan
    Rasmussen, Jeppe Norgaard
    Folke, Fredrik
    Hansen, Morten Lock
    Fosbol, Emil Loldrup
    Kober, Lars
    Norgaard, Mette Lykke
    Madsen, Mette
    Hansen, Peter Riis
    Torp-Pedersen, Christian
    EUROPEAN HEART JOURNAL, 2011, 32 (15) : 1900 - 1908
  • [3] Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality-A retrospective nationwide study
    Mogensen, Ulrik Madvig
    Andersson, Charlotte
    Fosbol, Emil Loldrup
    Schramm, Tina Ken
    Vaag, Allan
    Scheller, Nikolai Madrid
    Torp-Pedersen, Christian
    Gislason, Gunnar
    Kober, Lars
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 107 (01) : 104 - 112
  • [4] Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or exogenous insulin compared to metformin
    Bowker, SL
    Majumdar, SR
    Veugelers, P
    Johnson, JA
    DIABETES, 2005, 54 : A128 - A129
  • [5] Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes
    Johnson, JA
    Majumdar, SR
    Simpson, SH
    Toth, EL
    DIABETES CARE, 2002, 25 (12) : 2244 - 2248
  • [6] Decreased mortality associated with the use of metformin compared to sulfonylurea monotherapy in type 2 diabetes
    Johnson, JA
    Majumdar, S
    Simpson, SH
    Toth, E
    DIABETOLOGIA, 2001, 44 : A112 - A112
  • [7] Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study' (vol 32, pg 1900, 2011)
    Schramm, T. K.
    Gislason, G. H.
    Vaag, A.
    Rasmussen, J. N.
    Folke, F.
    Hansen, M. L.
    Fosbol, E. L.
    Kober, L.
    Norgaard, M. L.
    Madsen, M.
    Hansen, P. R.
    Torp-Pedersen, C.
    EUROPEAN HEART JOURNAL, 2012, 33 (10) : 1183 - 1183
  • [8] Dual therapy with sulphonylurea and insulin is associated with increased mortality as compared with metformin and insulin combined treatment
    Purcaru, M.
    Ioacara, S.
    Guja, C.
    Stegaru, D.
    Reghina, A.
    Georgescu, O.
    Martin, S.
    Mintici, L.
    Fica, S.
    DIABETOLOGIA, 2016, 59 : S355 - S355
  • [9] Investigational insulin secretagogues for type 2 diabetes
    Scheen, Andre J.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (04) : 405 - 422
  • [10] Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus
    Hemmingsen, Bianca
    Sonne, David Peick
    Metzendorf, Maria-Inti
    Richter, Bernd
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (10):
12345